United States – October 27, 2026 -- Families affected by Duchenne muscular dystrophy have early data on SGT-003, an investigational gene therapy from Solid Biosciences: 90 days after dosing, three boys showed average microdystrophin expression of 110%.

Global – October 27, 2026 -- Fifty-three boys with Duchenne muscular dystrophy have now received the investigational gene therapy SGT-003, and a Phase 3 trial is already enrolling patients in Australia and Canada. Solid Biosciences shared the update in a letter to the Duchenne community as the annual Parent Project Muscular Dystrophy (PPMD) conference got under way.

Dallas – October 16, 2026 -- The 21st annual Sam's Night raised $1.7 million, based on preliminary totals at press time, for Parent Project Muscular Dystrophy (PPMD), and donations are still open at SamsNight.org. The Killian family of Rockwall, Texas, hosted the fundraiser on Thursday, October 15, at Victory Social.

Washington – September 08, 2026 -- Parent Project Muscular Dystrophy (PPMD) is joining the global Duchenne and Becker muscular dystrophy community to mark World Duchenne Awareness Day on September 7th, a date recognized by the United Nations.